Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 167-174

  Hussain, Arif ^a,b,c   Wu, Yin ^b   Mirmiran, Alireza ^b   Dibiase, Steven ^d   Goloubeva, Olga ^a   Bridges, Benjamin ^a,b   Mannuel, Heather ^a,b,c   Engstrom, Christine ^c   Dawson, Nancy ^e   Amin, Pradip ^b   Kwok, Young ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

Concurrent chemoradiation; High risk prostate cancer; Multimodality therapy; Post prostatectomy radiation

Indexed keywords

AFRICAN AMERICAN; ANDROGEN DEPRIVATION; CONCURRENT CHEMORADIATION; GLEASON SCORES; LONG-TERM FOLLOW-UP; MULTIMODALITY THERAPY; PACLITAXEL; PELVIC RADIATION; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; TOTAL DOSE;

CHEMOTHERAPY; DISEASES; PATIENT MONITORING; RADIATION; TOXICITY; UROLOGY;

RADIOTHERAPY;

GONADORELIN AGONIST; METRONIDAZOLE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED RADIOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; EDEMA; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; FOLLOW UP; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GLEASON SCORE; GYNECOMASTIA; HEMATOCHEZIA; HEMATURIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; INFECTION; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL BODY RADIATION; PELVIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; TENESMUS; THROMBOCYTOPENIA; URINARY TRACT OBSTRUCTION; URINARY URGENCY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMORADIOTHERAPY; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM GRADING; PACLITAXEL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; URINATION DISORDERS;

EID: 83955165998     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.09.009     Document Type: Article

References (25)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 108
2. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827
3. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96-01 randomised controlled trial Lancet Oncol 6 2005 841 850
4. M. Roach III, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
5. M.S. Khil, J.H. Kim, and L.J. Bricker Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy Cancer J Sci Am 3 1997 289 296
6. M.J. Zelefsky, W.K. Kelly, and H.I. Scher Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer J Clin Oncol 18 2000 1936 1941
7. C.J. Ryan, M.J. Zelefsky, and G. Heller Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer Urology 64 2004 90 94
8. E. Ben-Josef, A.T. Porter, and S. Han Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results Int J Radiat Oncol Biol Phys 49 2001 699 703
9. P. Kumar, M. Perrotti, and R. Weiss Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate J Clin Oncol 22 2004 1909 1915
10. N.J. Sanfilippo, S.S. Taneja, and A. Chachoua Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer J Clin Oncol 26 2008 2973 2978
11. J. Ferrero, M. Bolla, and P. Maingon Concurrent and adjuvant docetaxel with three dimensional conformal radiation therapy (3-D CRT) for poor-risk localized prostate cancer: A phase II trial J Clin Oncol 25 18S 2007 5003
12. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
13. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial J Urol 181 2009 956 962
14. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
15. E.M. Messing, J. Manola, and J. Yao Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
16. G. Hanks, J.D. Lu, and M. Machtay RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate Proc ASTRO 48 2000 112 (abstract 4)
17. A. D'Amico, M. Loffredo, and A.A. Renshaw Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level J Clin Oncol 24 2006 4190 4195
18. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
19. M. Pilepich, K. Winter, and C. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
20. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial Lancet 373 2009 301 308
21. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
22. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
23. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy J Clin Oncol 24 2006 3979 3983
24. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
25. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer New Engl J Med 360 2009 2516 2527